NASDAQ:ACAD ACADIA Pharmaceuticals (ACAD) Stock Price, News & Analysis $27.29 -0.16 (-0.58%) Closing price 09/18/2026 04:00 PM EasternExtended Trading$27.22 -0.07 (-0.26%) As of 09/18/2026 07:55 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsInsider TradesNews and TrendsOptions ChainOwnershipSEC FilingsShort Interest About ACADIA Pharmaceuticals Stock (NASDAQ:ACAD) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get ACADIA Pharmaceuticals alerts:Sign Up Key Stats Today's Range$26.73▼$27.4850-Day Range$24.83▼$30.5752-Week Range$19.69▼$30.96Volume5.48 million shsAverage Volume1.26 million shsMarket Capitalization$4.70 billionP/E Ratio12.29Dividend YieldN/APrice Target$34.36Consensus RatingModerate Buy Company Overview ACADIA Pharmaceuticals Inc. is a biopharmaceutical company focused on developing and commercializing medicines for neurological and psychiatric disorders. The company is headquartered in San Diego, California, and conducts research and commercial activities primarily in the United States. ACADIA’s marketed products include NUPLAZID (pimavanserin), an atypical antipsychotic approved for the treatment of hallucinations and delusions associated with Parkinson’s disease psychosis. The company also markets DAYBUE (trofinetide), a therapy for Rett syndrome, a rare neurodevelopmental disorder. Founded in 1993, ACADIA continues to advance a pipeline of therapies for central nervous system conditions, including additional neurological and psychiatric disorders. Its research activities include the discovery, development and evaluation of potential treatments intended to address significant unmet medical needs.AI Generated. May Contain Errors. Read More ACADIA Pharmaceuticals Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks89th Percentile Overall ScoreACAD MarketRank™: ACADIA Pharmaceuticals scored higher than 89% of companies evaluated by MarketBeat, and ranked 42nd out of 897 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.4 / 5Analyst RatingModerate Buy Consensus RatingACADIA Pharmaceuticals has received a consensus rating of Moderate Buy. The company's average rating score is 2.78, and is based on no strong buy ratings, 14 buy ratings, 4 hold ratings, and no sell ratings.Upside PotentialACADIA Pharmaceuticals has a consensus price target of $34.36, representing about 25.9% upside from its current price of $27.29.Amount of Analyst CoverageACADIA Pharmaceuticals has been the subject of 14 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about ACADIA Pharmaceuticals' stock forecast and price target. Earnings and Valuation3.1 / 5Proj. Earnings Growth53.13% Earnings GrowthEarnings for ACADIA Pharmaceuticals are expected to grow by 53.13% in the coming year, from $0.64 to $0.98 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of ACADIA Pharmaceuticals is 12.29, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 42.25.Price to Earnings Ratio vs. SectorThe P/E ratio of ACADIA Pharmaceuticals is 12.29, which means that it is trading at a less expensive P/E ratio than the Healthcare sector average P/E ratio of about 214.59.Price to Book Value per Share RatioACADIA Pharmaceuticals has a P/B Ratio of 3.76. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about ACADIA Pharmaceuticals' valuation and earnings. Short Interest1.0 / 5Short Interest LevelBearish Percentage of Shares Shorted7.66% of the float of ACADIA Pharmaceuticals has been sold short.Short Interest Ratio / Days to CoverACADIA Pharmaceuticals has a short interest ratio ("days to cover") of 6.93.Change versus previous monthShort interest in ACADIA Pharmaceuticals has recently increased by 2.75%, indicating that investor sentiment is decreasing. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldACADIA Pharmaceuticals does not currently pay a dividend.Dividend GrowthACADIA Pharmaceuticals does not have a long track record of dividend growth. News and Social Media2.5 / 5News Sentiment1.06 News SentimentACADIA Pharmaceuticals has a news sentiment score of 1.06. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.56 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 4 news articles for ACADIA Pharmaceuticals this week, compared to 7 articles on an average week.Search InterestOnly 7 people have searched for ACAD on MarketBeat in the last 30 days. This is a decrease of -56% compared to the previous 30 days.MarketBeat FollowsOnly 2 people have added ACADIA Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Company Ownership2.1 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, ACADIA Pharmaceuticals insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $1,019,894.00 in company stock.Percentage Held by Insiders26.20% of the stock of ACADIA Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions96.71% of the stock of ACADIA Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about ACADIA Pharmaceuticals' insider trading history. Receive ACAD Stock News and Ratings via Email Sign-up to receive the latest news and ratings for ACADIA Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. ACAD Stock News HeadlinesACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) Receives Average Rating of "Moderate Buy" from AnalystsSeptember 19 at 2:15 AM | americanbankingnews.comACADIA Pharmaceuticals Inc. (ACAD)September 17 at 9:14 AM | finance.yahoo.comIran War: Why Is Trump Protecting THEM?A powerful Middle Eastern government is reportedly seeking US intelligence, targeting help, and military protection against Iran-backed forces. An anonymous source says that protection was only one side of an extraordinary bargain, with the other side potentially worth trillions of dollars to America. Addison Wiggin traced the deal linking Trump, Iran, and this government, and says the headlines look very different once you know who is involved. | Banyan Hill Publishing (Ad)Canaccord Genuity Reaffirms Their Buy Rating on ACADIA Pharmaceuticals (ACAD)September 5, 2026 | theglobeandmail.comAcadia Pharmaceuticals: Another Bite At The Alzheimer's AppleAugust 24, 2026 | seekingalpha.comACADIA Pharmaceuticals Wins EU Approval for Rett Syndrome's DrugAugust 24, 2026 | finance.yahoo.comEuropean Commission Approves DAYBU® (trofinetide) as the First and Only Treatment for Neurobehavioral Symptoms of Rett Syndrome in the European UnionAugust 24, 2026 | businesswire.comAnalysts Are Bullish on These Healthcare Stocks: ACADIA Pharmaceuticals (ACAD), Insmed (INSM)August 19, 2026 | theglobeandmail.comSee More Headlines ACAD Stock Analysis - Frequently Asked Questions How have ACAD shares performed this year? ACADIA Pharmaceuticals' stock was trading at $26.71 at the beginning of 2026. Since then, ACAD stock has increased by 2.2% and is now trading at $27.29. How were ACADIA Pharmaceuticals' earnings last quarter? ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) posted its quarterly earnings results on Tuesday, August, 4th. The biopharmaceutical company reported $0.18 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.07 by $0.11. ACADIA Pharmaceuticals's revenue was up 16.4% compared to the same quarter last year. Read the conference call transcript. Who are ACADIA Pharmaceuticals' major shareholders? Top institutional investors of ACADIA Pharmaceuticals include BlackRock Inc. (13.15%), Palo Alto Investors LP (1.66%), Braidwell LP (0.96%) and Bank of America Corp DE (0.75%). Insiders that own company stock include Stephen Davis, Mark C Schneyer, Brendan Teehan, Austin D Kim, Elizabeth A Garofalo, James Kihara, Elizabeth HZ Thompson, Laura Brege, Jennifer J Rhodes and James M Daly. View institutional ownership trends. How do I buy shares of ACADIA Pharmaceuticals? Shares of ACAD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of ACADIA Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some other companies that ACADIA Pharmaceuticals investors own include Humana (HUM), American Water Works (AWK), Voyager Therapeutics (VYGR), Waste Connections (WCN), The RMR Group (RMR), DiamondRock Hospitality (DRH) and AUO (AUOTY). Company Calendar Last Earnings8/04/2026Today9/19/2026Next Earnings (Estimated)11/04/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (2m+) 1-Year History Sep 25 Dec 25 Mar 26 Jun 26 Sep 26 ACAD's financial health is in the Green zone, according to TradeSmith. ACAD has been in this zone for over 2 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNASDAQ:ACAD CIK1070494 Webwww.acadia.com Phone(858) 558-2871Fax858-558-2872Employees798Year Founded1993Price Target and Rating Average Price Target for ACADIA Pharmaceuticals$34.36 High Price Target$49.00 Low Price Target$14.50 Potential Upside/Downside+25.9%Consensus RatingModerate Buy Rating Score (0-4)2.78 Research Coverage18 Analysts Profitability EPS (Trailing Twelve Months)$2.22 Trailing P/E Ratio12.29 Forward P/E Ratio42.64 P/E GrowthN/ANet Income$391 million Net Margins33.42% Pretax Margin10.66% Return on Equity9.03% Return on Assets6.79% Debt Debt-to-Equity RatioN/A Current Ratio3.39 Quick Ratio3.30 Sales & Book Value Annual Sales$1.07 billion Price / Sales4.39 Cash Flow$0.89 per share Price / Cash Flow30.76 Book Value$7.25 per share Price / Book3.76Miscellaneous Outstanding Shares172,310,000Free Float127,162,000Market Cap$4.70 billion OptionableOptionable Beta0.86 Social Links The Best Nuclear Energy Stocks to BuyNuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.Get This Free Report This page (NASDAQ:ACAD) was last updated on 9/20/2026 by MarketBeat.com Staff. From Our Partners$40,000,000,000,000The national debt just hit 40 trillion dollars, and the U.S. now spends more on interest payments than on its ...American Alternative | SponsoredTrump goes "all-in" on Grand Canyon energy breakthroughA drilling crew near the Grand Canyon uncovered a clean energy well producing nearly eight times the output of...Behind the Markets | SponsoredYour $29.97 book is free todayWhy Some Traders Skip Stocks Entirely You don't need a big account to trade options. In fact, options ca...Profits Run | SponsoredA “bloodbath” Is ComingReports suggest some Silicon Valley billionaires are stockpiling gold, guns, and gas masks - or leaving the co...TradeSmith | SponsoredMan who Predicted Trump 2016 Win: “Prepare for Mid-Term Meltdown”In 2016, major election models gave Hillary Clinton a 99% chance of winning - but former CIA and Pentagon advi...Paradigm Press | SponsoredThe hidden costs of a hands-off retirement accountContributing to your 401(k) consistently is good financial behavior - but contributing and optimizing are two ...SmartAsset | SponsoredThe trade I’ve been waiting for since 2011Ross Givens, Director of Research at Traders Agency, is calling for gold to reach $10,000 an ounce this superc...Traders Agency | SponsoredIran War: Why Is Trump Protecting THEM?A powerful Middle Eastern government is reportedly seeking US intelligence, targeting help, and military prote...Banyan Hill Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding ACADIA Pharmaceuticals Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share ACADIA Pharmaceuticals With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free ACAD Stock Alerts